Welcome to our dedicated page for Asensus Surgical news (Ticker: ASXC), a resource for investors and traders seeking the latest updates and insights on Asensus Surgical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Asensus Surgical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Asensus Surgical's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Asensus Surgical, Inc. (NYSE American: ASXC) has announced the release date for its 2023 first quarter financial and operational results, set for May 11, 2023, after market close. The company will conduct a conference call later that day at 4:30 p.m. ET to discuss these results, which can be accessed via telephone or through a live audio webcast. Asensus is focused on transforming surgery with its Performance-Guided Surgery™ approach, leveraging technologies including the Senhance Surgical System and the upcoming LUNA™ Surgical System. These innovations aim to enhance surgical outcomes by integrating machine vision and deep learning into the surgical process.
Asensus Surgical, Inc. announced a partnership with Fukuoka Tokushukai Hospital in Japan to lease the Senhance® Surgical System. This collaboration marks a significant milestone as the hospital is part of Japan's second largest private hospital system, enhancing the company's presence in a fast-growing market. Asensus aims to accelerate the adoption of Digital Laparoscopy in Japan, a region identified as a key focus for expansion. The Senhance System is unique for its haptic feedback capabilities, enhancing surgical precision. The CEO of Fukuoka Tokushukai Hospital emphasized the system's role in improving patient outcomes through advanced robotic surgery capabilities. This agreement reflects Asensus Surgical's commitment to pioneering Performance-Guided Surgery™ and signifies an important step in their global strategy.
Asensus Surgical, Inc. (NYSE American: ASXC) has announced participation in the H.C. Wainwright In-Person Bio-Connect Investor Conference. CEO Anthony Fernando and CFO Shameze Rampertab are set to engage in a fireside chat on May 2, 2023, at 11:30 am ET. Interested parties can access the conference webcast via the company's investor relations page, with replays available for 90 days. Asensus is focused on enhancing surgical outcomes through its innovative Performance-Guided Surgery™ model. The company is developing the LUNA™ Surgical System, building on its Digital Laparoscopy and Senhance® Surgical System. The Senhance system is currently available in several regions including the US, EU, and Japan. For further insights, visit the company's websites.
Asensus Surgical, Inc. (ASXC) announced the FDA 510(k) clearance for the Senhance® System, the first digital laparoscopic surgery solution for pediatric patients in the U.S. This system allows minimally invasive procedures with its 3mm instruments and 5mm camera scope, enhancing precision and safety through haptic feedback and advanced clinical intelligence. Already in use in Europe and Japan, this clearance aims to address the unique surgical needs of pediatric patients. Surgeons have successfully utilized the system for various procedures, paving the way for improving outcomes in this underserved patient population.